BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 37257705)

  • 1. Elucidating the pharmacological effects of Compound Kushen injection on MYC-P15-CCND1 signaling pathway in nasopharyngeal carcinoma - An in vitro study.
    Wu Z; Wu C; Shi J; Huang Z; Lu S; Tan Y; You R; Hai L; Huang J; Guo S; Gao Y; Jin Z; Tao X; You L; Wu J
    J Ethnopharmacol; 2023 Oct; 315():116702. PubMed ID: 37257705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An advanced network pharmacology study to explore the novel molecular mechanism of Compound Kushen Injection for treating hepatocellular carcinoma by bioinformatics and experimental verification.
    Lu S; Meng Z; Tan Y; Wu C; Huang Z; Huang J; Fu C; Stalin A; Guo S; Liu X; You L; Li X; Zhang J; Zhou W; Zhang X; Wang M; Wu J
    BMC Complement Med Ther; 2022 Mar; 22(1):54. PubMed ID: 35236335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study on the mechanisms of compound Kushen injection for the treatment of gastric cancer based on network pharmacology.
    Zhou W; Wu J; Zhu Y; Meng Z; Liu X; Liu S; Ni M; Jia S; Zhang J; Guo S
    BMC Complement Med Ther; 2020 Jan; 20(1):6. PubMed ID: 32020871
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms of Compound Kushen Injection for the treatment of bladder cancer based on bioinformatics and network pharmacology with experimental validation.
    Zhang LH; Zhang WY; Xiong JM; Duan XM; Hai LN; Zhang YL; Zhang MM; Qin GF; Zhang GW
    Chin J Nat Med; 2022 Jan; 20(1):43-53. PubMed ID: 35101249
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated bioinformatics analysis to decipher molecular mechanism of compound Kushen injection for esophageal cancer by combining WGCNA with network pharmacology.
    Zhou W; Wu J; Zhang J; Liu X; Guo S; Jia S; Zhang X; Zhu Y; Wang M
    Sci Rep; 2020 Jul; 10(1):12745. PubMed ID: 32728182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Compound Kushen injection inhibits EMT of gastric cancer cells via the PI3K/AKT pathway.
    Li L; Wang K; Liu Z; Lü Y; Wang C; Yi X; Guo J
    World J Surg Oncol; 2022 May; 20(1):161. PubMed ID: 35590327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Network Pharmacology-Based Study on the Molecular Biological Mechanism of Action for Compound Kushen Injection in Anti-Cancer Effect.
    He R; Ou S; Chen S; Ding S
    Med Sci Monit; 2020 Jan; 26():e918520. PubMed ID: 31892693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Uncovering the anticancer mechanism of Compound Kushen Injection against HCC by integrating quantitative analysis, network analysis and experimental validation.
    Gao L; Wang KX; Zhou YZ; Fang JS; Qin XM; Du GH
    Sci Rep; 2018 Jan; 8(1):624. PubMed ID: 29330507
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Network pharmacology, molecular docking and experimental study of CEP in nasopharyngeal carcinoma.
    Yang J; Qin L; Zhou S; Li J; Tu Y; Mo M; Liu X; Huang J; Qin X; Jiao A; Wei W; Yang P
    J Ethnopharmacol; 2024 Apr; 323():117667. PubMed ID: 38159821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Compound Kushen Injection intervenes metabolic reprogramming and epithelial-mesenchymal transition of HCC via regulating β-catenin/c-Myc signaling.
    Wang KX; Du GH; Qin XM; Gao L
    Phytomedicine; 2021 Dec; 93():153781. PubMed ID: 34649212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Nasopharyngeal carcinoma mechanism of sanguinarine based on network pharmacology and molecular docking.
    Fan JY; Liu J; Zhang WQ; Lin T; Hu XR; Zhou FL; Tang L; He YC; Shi HJ
    Medicine (Baltimore); 2023 Dec; 102(48):e36477. PubMed ID: 38050231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A network pharmacology approach and experimental validation to investigate the anticancer mechanism and potential active targets of ethanol extract of Wei-Tong-Xin against colorectal cancer through induction of apoptosis via PI3K/AKT signaling pathway.
    Lin F; Zhang G; Yang X; Wang M; Wang R; Wan M; Wang J; Wu B; Yan T; Jia Y
    J Ethnopharmacol; 2023 Mar; 303():115933. PubMed ID: 36403742
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Advanced Systems Pharmacology Strategy Reveals
    Zhou W; Wu C; Zhao C; Huang Z; Lu S; Fan X; Tan Y; Stalin A; You R; Liu X; Zhang J; Wu Z; Wu J
    Front Cell Dev Biol; 2021; 9():742421. PubMed ID: 34646828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A network pharmacology approach to reveal the pharmacological targets and biological mechanism of compound kushen injection for treating pancreatic cancer based on WGCNA and in vitro experiment validation.
    Wu C; Huang ZH; Meng ZQ; Fan XT; Lu S; Tan YY; You LM; Huang JQ; Stalin A; Ye PZ; Wu ZS; Zhang JY; Liu XK; Zhou W; Zhang XM; Wu JR
    Chin Med; 2021 Nov; 16(1):121. PubMed ID: 34809653
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploring the pharmacological mechanism of compound kushen injection in the treatment of breast cancer using
    Ye Y; Zhang B; Liang Q; Wang D; Bai F; Li Y; Wei L; Li L; Huang H; Tang Y
    Front Oncol; 2022; 12():946758. PubMed ID: 36016606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luteolin Isolated from
    Xiong Y; Zhong W; Liu J; Cheng B; Fan J; Zhou F; He L; Tian D; He Y
    Biomed Res Int; 2022; 2022():9740066. PubMed ID: 36588531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of Compound Kushen Injection and cisplatin shows synergistic antitumor activity in p53-R273H/P309S mutant colorectal cancer cells through inducing apoptosis.
    Wu X; Lu Y; Qin X
    J Ethnopharmacol; 2022 Jan; 283():114690. PubMed ID: 34597653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A metabolic data-driven systems pharmacology strategy for decoding and validating the mechanism of Compound Kushen Injection against HCC.
    Wang KX; Chen YP; Lu AP; Du GH; Qin XM; Guan DG; Gao L
    J Ethnopharmacol; 2021 Jun; 274():114043. PubMed ID: 33753143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the Molecular Mechanism of
    Xu R; Yang X; Tao Y; Luo W; Xiong Y; He L; Zhou F; He Y
    J Healthc Eng; 2022; 2022():6277139. PubMed ID: 35463684
    [TBL] [Abstract][Full Text] [Related]  

  • 20. APLNR is involved in ATRA-induced growth inhibition of nasopharyngeal carcinoma and may suppress EMT through PI3K-Akt-mTOR signaling.
    Liu Y; Liu Q; Chen S; Liu Y; Huang Y; Chen P; Li X; Gao G; Xu K; Fan S; Zeng Z; Xiong W; Tan M; Li G; Zhang W
    FASEB J; 2019 Nov; 33(11):11959-11972. PubMed ID: 31408612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.